European Society of Cardiology incorporates iFR technology into updated guidelines for revascularization

- iFR-guided strategy now deemed beneficial in the assessment of the functional significance of intermediate coronary stenosis
- Technique using iFR-guided strategy is non-inferior to FFR for guiding decisions for intervening on immediate lesions with stable angina or NSTE ACS     

AMSTERDAM and MUNICH, Aug. 28, 2018 /PRNewswire/ -- Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that the European Society of Cardiology has incorporated instantaneous wave-free ratio (iFR) into its updated revascularization guidelines. The new guidelines have provided the highest recommendation (class I A) for iFR alongside fractional flow reserve (FFR) for the objective assessment of the hemodynamic relevance of coronary lesions. In 2017, the DEFINE-FLAIR and iFR Swedeheart studies, the largest randomized coronary physiology outcome studies published to date, showcased iFR as a non-inferior method to FFR during risk stratification in coronary stenosis. iFR is an innovative pressure-derived index unique to Philips, allowing a simplified hyperemia-free physiological assessment of coronary blockages to identify the appropriate therapy for each patient.

"We welcome the inclusion of iFR into the ESC's revascularization guidelines," said Bert van Meurs, Business Leader Image Guided Therapy at Philips. "The DEFINE-FLAIR and iFR Swedeheart studies have provided significant clinical validation of iFR, which has been shown to improve patient outcomes, reduce costs and increase patient comfort for the treatment of coronary artery disease in comparison to an FFR-guided strategy. As a leader in image-guided therapy we provide solutions that confirm the right therapy for each patient, supporting improved outcomes."

Procedure tailored for patient care
Ischemic heart disease (IHD) causes the highest rate of disability and death compared to any other illness in the world and also incurs the greatest economic costs. Of the approximately 17.7 million people who died from cardiovascular diseases globally in 2015, a total of 7.4 million were a result of coronary heart disease ¹. Philips began offering iFR technology as an alternative to FFR in 2013 in Europe and 2014 in the US. It has since become a prevalent method for the assessment of lesions. The technology offers a procedure that provides functional measurement while reducing patient discomfort by 90 percent, reducing costs by approximately 10 percent per patient over a one-year average and reducing time spent in the lab by 10 percent.

Building a seamless cardiovascular care ecosystem
Healthcare providers have a heightened focus on providing the highest quality care while managing their operational costs. Philips has recognized this need and developed an integrated portfolio of products and solutions that enables healthcare providers to improve diagnosis and care for cardiovascular patients. Philips is continuing to identify opportunities to build cardiovascular healthcare models that drive improved treatment and outcomes, simplify data gathering, reduce costs and improve patient care through innovative care and pathway management.

For more information on Philips and iFR, please visit here. Visit the Philips Stand #H200, Hall A3 at ESC to experience our innovative cardiology portfolio. Follow the #ESC2018 conversation with @PhilipsLiveFrom throughout the event.

¹ Cardiovascular diseases (CVDs). (n.d.). Retrieved from http://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)

For further information, please contact:

Mark Groves
Philips Group Press Office
Tel: +31 631 639 916
Email: mark.groves@philips.com

Fabienne van der Feer
Philips Image Guided Therapy
Tel: +31 622 698 001
Email: fabienne.van.der.feer@philips.com

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2017 sales of EUR 17.8 billion and employs approximately 74,000 employees with sales and services in more than 100 countries. News about Philips can be found at http://www.philips.com/newscenter.

 

View original content with multimedia:http://www.prnewswire.com/news-releases/european-society-of-cardiology-incorporates-ifr-technology-into-updated-guidelines-for-revascularization-300703205.html

SOURCE Royal Philips

   
Company Codes: NYSE:PHG, EuronextAmsterdam:PHIA